Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran in children with homozygous familial hypercholesterolemia
NL-OMON59348Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in homozygous familial hypercholesterolemia (HoFH) comparing Inclisiran with Placebo (2 arms). Primary endpoint: Percentage change in LDL-C from baseline to Day 330. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON59348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59348.